CATX — Perspective Therapeutics Income Statement
0.000.00%
- $671.76m
- $492.83m
- $1.43m
- 58
- 68
- 74
- 74
Annual income statement for Perspective Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.31 | 9.68 | 10.1 | 10.8 | 1.43 |
Cost of Revenue | |||||
Gross Profit | 3.05 | 5.12 | 5.12 | 4.62 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.6 | 13.2 | 13.5 | 18.2 | 42.4 |
Operating Profit | -5.25 | -3.48 | -3.45 | -7.39 | -40.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.14 | -3.45 | -3.39 | -7.27 | -40.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.14 | -3.45 | -3.39 | -7.27 | -37.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -5.14 | -3.45 | -3.39 | -7.27 | -46.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.16 | -3.46 | -3.39 | -7.27 | -46.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.772 | -0.511 | -0.326 | -0.512 | -1.4 |